Why REMS Abuse Doesn't Belong In Antitrust Litigation
When asked to identify the "next generation" of antitrust claims in the pharmaceutical industry, many practitioners, industry publications and conference organizers would respond with an acronym: REMS. Indeed, in recent years...To view the full article, register now.
Already a subscriber? Click here to view full article